Advanced Targeted Radiofluorescence
Multimodality Radioligand Theranostic
Novel Drug for Disease Management
At Antelope Surgical Solutions, Inc., we are driven by our passion for developing cutting-edge products that will revolutionize the medical biotechnology industry. Since our founding in 2020, we’ve established a GMP manufacturing facility equipped with robotic high-throughput synthesis capabilities. Our innovative multimodal small molecule, designed for diagnostic, radiotherapeutic, and fluorescence-guided surgical applications, is built upon our patented, first-of-its-kind chemical syntheses. With a team of dedicated professionals, we are committed to inspiring and leading with our groundbreaking ideas and expertise.
Redefining the field of image guided surgery
Tenets
Definitive in vivo identification of tumors and metastases during surgery
PET, MR, CT, US, and SPECT imaging techniques often lack the resolution needed to accurately define the spatial boundaries of lymph node metastases and positive margins, limiting the crucial information available to surgeons during procedures. Antelope Surgical Solutions has promising preliminary data in fluorescence-guided surgery and is actively working on developing additional imaging agents for future applications to enhance surgical precision.
GMP Synthesis
Development pipelines for single-modality diagnostic imaging agents typically take 8 to 10 years and cost between $100-200 million. Antelope Surgical's current pipeline includes two imaging agents, with plans to expand and introduce more in the future.
Proprietary Solutions
We aim to have the first multimodality radioligand therapeutic and fluorescent agent approved by the US Food and Drug Administration on the market.
Streamlining of long-term pipelines in accordance with GMP standards
Get in touch
Reach out to us with further questions or inquiries about our work, or to stay in touch about prospective projects and recruitment.